Proliferative diabetic retinopathy
Conditions
Interventions
Trade Name: Avastin (bevacizumab)
Product Name: Avastin (bevacizumab)
Pharmaceutical Form: Injection*
Sponsors
Royal Victoria Eye and Ear hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 20 patients with new onset, bilateral, high risk proliferative diabetic retinopathy (DRS criteria) will be recruited. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Only eye Women of childbearing potential
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the effectiveness of intravitreal bevacizumab in treating proliferative diabetic retinopathy when compared with conventional treatment. Primary outcomes: 1. Best corrected visual acuity at 6 months 2. Neovascularisation. 3. Need for panretinal photocoagulation. 4. Need for vitrectomy 5. Median deviation in visual fields at 6 months ;Secondary Objective: Secondary outcomes: Quality of life (VFQ 25 questionnaire). ;Primary end point(s): Primary outcomes: 1. Best corrected visual acuity at 6 months 2. Neovascularisation. 3. Need for panretinal photocoagulation. 4. Need for vitrectomy 5. Median deviation in visual fields at 6 months | — |
Countries
Ireland
Outcome results
None listed